



Resources for Genetics Professionals – Genetic Disorders Associated with Founder Variants Common in the Costa Rican Population

Stephanie E Wallace, MD^{1,2}

Created: June 30, 2022.

A founder variant is a pathogenic variant observed at high frequency in a specific population due to the presence of the variant in a single ancestor or small number of ancestors. The presence of a founder variant can affect the approach to molecular genetic testing. When one or more founder variants account for a large percentage of all pathogenic variants found in a population, testing for the founder variant(s) may be performed first. The table below includes common founder variants – here defined as **three or fewer variants that account for more than 50% of the pathogenic variants identified in a single gene in individuals of a specific ancestry** – in individuals of Costa Rican ancestry. Note: Pathogenic variants that are common worldwide due to a DNA sequence hot spot are not considered founder variants and thus are not included.

Table. Genetic Disorders Associated with Founder Variants Common in the Costa Rican Population

Gene	Disorder	MOI	DNA Nucleotide Change	Predicted Protein Change	% of Pathogenic Variants in Gene ¹	Carrier Frequency	Ethnicity	Reference Sequences	References
ATM	Ataxia-telangiectasia	AR	c.5908C>T	p.Gln1970Ter	61%	Unknown	Costa Rican	NM_000051.4 NP_000042.3	Telatar et al [1998]
			c.7449G>A	p.Trp2483Ter	12%				
			c.4507C>T	p.Gln1503Ter	10%				
ATP7B	Wilson disease	AR	c.3809A>G	p.Asn1270Ser	61%	1/72 ²	Costa Rican	NM_000053.4 NP_000044.2	Shah et al [1997]
CLN6	Ceroid lipofuscinosis (OMIM 601780)	AR	c.214G>T	p.Glu72Ter	~85%	Unknown	Costa Rican	NM_017882.3 NP_060352.1	Gao et al [2002], Wheeler et al [2002], Sharp et al [2003]

Author Affiliations: 1 Senior Editor, GeneReviews; Email: editor2@uw.edu. 2 Clinical Professor, Pediatrics, University of Washington, Seattle, Washington; Email: editor2@uw.edu.

Table. continued from previous page.

Gene	Disorder	MOI	DNA Nucleotide Change	Predicted Protein Change	% of Pathogenic Variants in Gene ¹	Carrier Frequency	Ethnicity	Reference Sequences	References
<i>GALK1</i>	Galactokinase deficiency (OMIM 230200)	AR	c.1144C>T	p.Gln382Ter	~92%	1/190 ²	Costa Rican	NM_000154.2 NP_000145.1	Kolosha et al [2000]
<i>PNKP</i>	Axonal Charcot-Marie-Tooth disease type 2B2 (OMIM 605589)	AR	c.1221_1223delCAC	p.Thr408del	~100% ³	Unknown	Costa Rican	NM_007254.4 NP_009185.2	Leal et al [2018]
			c.1549C>T	p.Gln517Ter					
<i>RPE65</i>	Leber congenital amaurosis	AR	c.292_311del20	p.Ile98HisfsTer26	30%	Unknown	Costa Rican	NM_000329.3 NP_000320.1	Glen et al [2019]
			c.1338G>T	p.Arg446Ser	30%				
			c.242G>T	p.Arg81Ile	25%				
			c.419G>A	p.Gly140Glu	12.5%				
<i>SLC12A1</i>	Bartter syndrome, type 1 (OMIM 601678)	AR	c.1875G>A	p.Trp625Ter	57%	~1/145 ²	Costa Rican	NM_000338.3 NP_000329.2	Kurtz et al [1997]
<i>TCIRG1</i>	Osteopetrosis (OMIM 259700)	AR	c.1213G>A	p.Gly405Arg	~66%	~1/86 ²	Costa Rican	NM_006019.4 NP_006010.2	Sobacchi et al [2001]
			c.1331G>T	p.Arg444Leu	~33%				
<i>UBR1</i>	Johanson-Blizzard syndrome (OMIM 243800)	AR	c.1537C>T	p.Glu513Ter	~100% ³	Unknown	Costa Rican	NM_174916.3 NP_777576.1	Sukalo et al [2014]

Included if ≤ 3 pathogenic variants account for $\geq 50\%$ of variants identified in a specific ethnic group

AR = autosomal recessive; MOI = mode of inheritance

1. This percentage does not account for the possibility of rare *de novo* pathogenic variants occurring in this population.

2. Calculated carrier frequency based on the incidence of the disorder in individuals of Costa Rican ancestry; Estimated carrier frequency is not based on molecular testing of the population.

3. To date, no additional pathogenic variants in this gene have been reported in individuals of Costa Rican descent.

References

- Gao H, Boustany RM, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, Gillis T, Qin X, Liu S, Donahue LR, Bronson RT, Faust JR, Stout D, Haines JL, Lerner TJ, MacDonald ME. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. *Am J Hum Genet.* 2002;70:324–35. PubMed PMID: 11791207.
- Glen WB Jr, Peterseim MMW, Badilla R, Znoyko I, Bourg A, Wilson R, Hardiman G, Wolff D, Martinez J. A high prevalence of biallelic RPE65 mutations in Costa Rican children with Leber congenital amaurosis and early-onset retinal dystrophy. *Ophthalmic Genet.* 2019;40:110–7. PubMed PMID: 30870047.

- Kolosha V, Anoaia E, de Cespedes C, Gitzelmann R, Shih L, Casco T, Saborio M, Trejos R, Buist N, Tedesco T, Skach W, Mitelmann O, Ledee D, Huang K, Stambolian D. Novel mutations in 13 probands with galactokinase deficiency. *Hum Mutat.* 2000;15:447–53. PubMed PMID: 10790206.
- Kurtz CL, Karolyi L, Seyberth HW, Koch MC, Vargas R, Feldmann D, Vollmer M, Knoers NV, Madrigal G, Guay-Woodford LM. A common NKCC2 mutation in Costa Rican Bartter's syndrome patients: evidence for a founder effect. *J Am Soc Nephrol.* 1997;8:1706–11. PubMed PMID: 9355073.
- Leal A, Bogantes-Ledezma S, Ekici AB, Uebe S, Thiel CT, Sticht H, Berghoff M, Berghoff C, Morera B, Meisterernst M, Reis A. The polynucleotide kinase 3'-phosphatase gene (PNKP) is involved in Charcot-Marie-Tooth disease (CMT2B2) previously related to MED25. *Neurogenetics.* 2018;19:215–25. PubMed PMID: 30039206.
- Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, Parano E, Pavone L, Evgrafov O, Ivanova-Smolenskaya IA, Annerén G, Westermark K, Urrutia FH, Penchaszadeh GK, Sternlieb I, Scheinberg IH, Gilliam TC, Petrukhin K. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. *Am J Hum Genet.* 1997;61:317–28. PubMed PMID: 9311736.
- Sharp JD, Wheeler RB, Parker KA, Gardiner RM, Williams RE, Mole SE. Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. *Hum Mutat.* 2003;22:35–42. PubMed PMID: 12815591.
- Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, Babul-Hirji R, Baric I, Canham N, Chitayat D, Dupuis-Girod S, Ellis I, Etzioni A, Fasth A, Fisher A, Gerritsen B, Gulino V, Horwitz E, Klamroth V, Lanino E, Mirolo M, Musio A, Matthijs G, Nonomaya S, Notarangelo LD, Ochs HD, Superti Furga A, Valiaho J, van Hove JL, Vihinen M, Vujic D, Vezzoni P, Villa A. The mutational spectrum of human malignant autosomal recessive osteopetrosis. *Hum Mol Genet.* 2001;10:1767–73. PubMed PMID: 11532986.
- Sukalo M, Fiedler A, Guzmán C, Spranger S, Addor MC, McHeik JN, Oltra Benavent M, Cobben JM, Gillis LA, Shealy AG, Deshpande C, Bozorgmehr B, Everman DB, Stattin EL, Liebelt J, Keller KM, Bertola DR, van Karnebeek CD, Bergmann C, Liu Z, Düker G, Rezaei N, Alkuraya FS, Oğur G, Alrajoudi A, Venegas-Vega CA, Verbeek NE, Richmond EJ, Kirbiyik O, Ranganath P, Singh A, Godbole K, Ali FA, Alves C, Mayerle J, Lerch MM, Witt H, Zenker M. Mutations in the human UBR1 gene and the associated phenotypic spectrum. *Hum Mutat.* 2014; 2014;35:521–31. PubMed PMID: 24599544.
- Telatar M, Wang S, Castellvi-Bel S, Tai LQ, Sheikhavandi S, Regueiro JR, Porras O, Gatti RA. A model for ATM heterozygote identification in a large population: four founder-effect ATM mutations identify most of Costa Rican patients with ataxia telangiectasia. *Mol Genet Metab.* 1998;64:36–43. PubMed PMID: 9682216.
- Wheeler RB, Sharp JD, Schultz RA, Joslin JM, Williams RE, Mole SE. The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in *nclf* mutant mice encodes a novel predicted transmembrane protein. *Am J Hum Genet.* 2002;70:537–42. PubMed PMID: 11727201.

Revision History

- 30 June 2022 (sw) Initial posting

License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: admasst@uw.edu.